Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following TAVI Procedure

Aortic Valve Stenosis Clinical Trial

— PostCorE  

Official title:

Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following Medtronic CoreValve or Other Self-Expanding TAVI Procedure (PostCorE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02472106
• Other study ID #: 1302-001
• Status: Completed
• Phase: N/A
• First received: May 28, 2015
• Last updated: August 30, 2016
• Start date: June 2015
• Est. completion date: August 2016

Study information

• Verified date: August 2016
• Source: InterValve, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Observational

Clinical Trial Summary

This study is designed to monitor the safety and performance of the V8 balloon when used as a postdilatation balloon in self-expanding Transcatheter Aortic Valve Implantation (TAVI) device procedures. The study product is CE marked for balloon aortic valvuloplasty (BAV), and is being investigated for an expanded intended use.

Description:

The study is a prospective, multi-center, single arm open-label clinical study involving up to 5 centers and a minimum of 20 subjects. Up to 50 subjects may be enrolled in this study. The first 3 post-dilatation procedures for each investigator will be considered roll-ins and not included in the main study analyses. Subjects will exit the study at hospital discharge or 7 days post treatment, whichever comes first. The expected duration of the clinical investigation is approximately 6 months.

Subjects implanted with the CoreValve or other commercially available self-expanding TAVI and with the use of the V8 as a postdilatation balloon may be enrolled in this study. The subject will exit the study after the predischarge ECHO where the Paravalvular Leak (PVL) measurements are taken or resolution of a V8 related AE (if applicable).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Subjects with severe symptomatic aortic stenosis (AS) indicated and scheduled for a transcatheter aortic valve implant (TAVI) with the Medtronic CoreValve or another self-expanding TAVI device.

• The TAVI device size is determined preoperatively with CTA according to standard guidelines. Patients may undergo transfemoral, subclavian, or transaortic approach.

• Balloon postdilatation (BPD) is carried out after CoreValve or other self-expanding TAVI device implantation if, based on operator's judgment, BPD is indicated because of presence of paravalvular leak (PVL).

• Hemodynamically stable for 3 - 10 minutes after the TAVI procedure.

• Probable survival to hospital discharge.

• Subject is competent, willing to comply with evaluations, understands risks, benefits and alternatives and has signed the Informed Consent Form.

Exclusion Criteria:

• Cardiogenic shock, as defined by a consistent systolic blood pressure <80 mmHg off vasopressors or <90 mmHg on vasopressors.

• PVL occurring secondary to excessively high or low valve positioning.

• Trauma or significant structural damage to underlying native tissue calls for emergent intervention or threatens long-term outcome prior to the BPD.

• Patients receiving two valves (i.e. aortic THV valve in valve).

• Patients with AS secondary to congenital valve disease including bicuspid aortic valve.

• PVL occurring due to TAVI device under sizing. Example of determining the undersizing is to calculate the Cover Index which represents the percent of over sizing of the nominal transcatheter heart valve (THV) area compared to the measured native valve annulus area. Under sizing is defined as TAVI screening CTA with a pre procedure cover index by area of <5%.

• Vulnerable subjects and any subjects incapable of giving consent, including patients with incurable diseases, patients in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, minors, and subjects with cognitive impairment, such as persons with a mental illness or dementia.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Aortic Valve Stenosis
• Constriction, Pathologic

Intervention

Device:
• Post-dilatation
Post-dilatation in self-expanding TAVI device procedures

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
InterValve, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy Endpoint: V8 Device Performance	Rate of successful V8 balloon fixation within the TAVI prosthesis: during rapid ventricular pacing, proximal and distal balloon segments are securely fixed on either side of the native aortic valve annulus following inflation	Intra-Procedure	No
Primary	Safety Endpoint: Serious Adverse Events (SAE)	The composite of SAEs as defined by the Valve Academic Research Consortium (VARC II)	Intra-procedure until discharge or 7 days post-procedure, whichever comes first. (Typical discharge is expected to be within 7 days.)	Yes
Secondary	Efficacy Endpoint: Degree of Paravalvular Leak (PVL)	PVL determined by collating as many data points as possible using TTE, TEE, aortic root angiography, and/or hemodynamic measurements	Intra-Procedure	No
Secondary	Efficacy Endpoint: Procedural Parameter - V8 Dimension	Size of V8(s) used during procedure	Intra-Procedure	No
Secondary	Efficacy Endpoint: Procedural Parameter - CoreValve Dimension	Size of CoreValve(s) used during procedure	Intra-Procedure	No
Secondary	Efficacy Endpoint: Procedural Parameter - Aortic Valve Measurement	Aortic Valve measurements performed during procedure	Intra-Procedure	No
Secondary	Safety Endpoint: 24hr Complication	AE(s) defined in protocol attributable to V8 balloon post-dilatation (BPD) procedure	24 hours post-procedure	Yes